Kailera CEO Buys 38,000 Shares at $5.25, Hinting at a Hidden Upside Ahead of Obesity‑Drug Push
CEO insider buy of Kailera shares at $5.25 shows bullish outlook; signals undervalued growth, pipeline potential, and possible upside.
3 minutes to read
KAILERA THERAPEUTICS INC